New York Asthma & Allergy Society (NYAAS) Scientific Meetings

BioCryst will attend the 2026 New York Asthma & Allergy Society (NYAAS) Scientific Meetings on Sept 09, 2026.

Arizona Allergy and Asthma Society

BioCryst will attend the 2026 Arizona Allergy and Asthma Society from Sept 11 – Sept 13, 2026.

Greater Washington AAI Society (GWAAIS)

BioCryst will attend the 2026 Greater Washington AAI Society (GWAAIS) on Sept 16, 2026.

Southeastern Allergy, Asthma, and Immunology (SEAAI)

BioCryst will attend the 2026 Southeastern Allergy, Asthma, and Immunology (SEAAI) from Sept 17 – Sept 22, 2026.

  • Clinical Outcomes With Navenibart According to Baseline Attack Rate, Body Mass Index, and Age: Results of the ALPHA-STAR Trial
    EAACI | 2026 | HAE
  • Hereditary Angioedema Attack Frequency and Severity According to Individuals Taking Berotralstat for Long-Term Prophylaxis
    EAACI | 2026 | HAE
  • Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilising Professional Care in Paediatric Patients Aged 2 to <12 years: APeX-P Results Through 48 Weeks
    EAACI | 2026 | HAE
  • Reductions in Healthcare Resource Utilization in Adolescents with Hereditary Angioedema on Berotralstat
    EAACI | 2026 | HAE
  • Hereditary Angioedema Attack Rates among Patients with Normal C1 Esterase Inhibitor Before and After Switching from Another Long-Term Prophylaxis to Berotralstat
    EAACI | 2026 | HAE

Have questions about any of our medicines that are approved or in development, or would you like to be connected with an MSL?

Have questions about our company?